Shares of Mateon Therapeutics (OTCQX: MATN) are up 26% this morning after the company released preliminary data from its phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The data show that two of four patients achieved a complete remission after one cycle of treatment. Additionally, there were no dose-limiting toxicities observed in the fifth cohort and OXi4503 continued to have a favorable safety profile. “Every dose of OXi4503 tested in this study has shown encouraging signs of efficacy and a favorable safety profile, with the highest doses showing the earliest and best activity,” Mateon president and CEO William D. Schwieterman, M.D., stated in the news release.
To view the full press release, visit: http://nnw.fm/t9Ch6
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action. Mateon believes it can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels. Mateon is committed to leveraging its intellectual property and the product development expertise of the highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide. For more information, visit www.mateon.com.
More from NetworkNewsBreaks
ChineseInvestors.com, Inc. (CIIX) Announces Establishment of Hemp Education Center
Patriot One Technologies (PTOTF) Offers Game-Changing Tool in Fight Against Terrorism
Moxian, Inc. (NASDAQ: MOXC) Taking Part in Transformation of China’s Economy
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com